Juliette is a Partner at Forbion, where she is a core member of the investment team.

She invests and builds companies across therapeutic areas and modalities. She currently serves as a board member for NewAmsterdam Pharma, Mestag Therapeutics and is an observer on a stealth inflammation company.

Prior to joining Forbion, Juliette was a Principal at Novartis Venture Fund (NVF) based in Cambridge (USA) where she sat on the boards of TScan Therapeutics and Annexon Biosciences as an observer. Juliette was also leading the management NVF’s public equities. Before that, Juliette was a Senior Manager of Strategy at Novartis AG, where she worked with the senior executive team of the Pharma division. She spent the beginning of her career in management consulting at McKinsey and Company focusing on Pharma and Biotech, based out of the Swiss and then its New York offices.

Juliette graduated with distinction from Harvard Business School in 2015 (MBA) and received her MSc in Physics (Suma Cum Laude) from EPFL (Lausanne, Swiss Federal Institute of Technology) in 2010.